文献速递神经肌肉病

在肌萎缩侧索硬化临床试验中培育患者偏好:患者排序功能顺序的信度与预后价值

Cultivating Patient Preferences in ALS Clinical Trials: Reliability and Prognostic Value of the Patient-Ranked Order of Function.
PubMed 文献 · Neurology · 2024-06-14

研究基于荷兰人群登记库开展12个月在线问卷调查,评估PROOF终点所用不同患者偏好集的信度与预后价值。共611例ALS患者随访生存,382例纳入重测信度研究;各版本PROOF信度优良, ICC为0.89(95%CI 0.87-0.91)至0.97(95%CI 0.97-0.98),均p<0.001,且均能强预测总生存。

要点

  • 各版本PROOF重测信度优良,ICC为0.89至0.97,均p<0.001。
  • 基线至第2周无系统性差异,平均秩差范围为-1至-3,均p>0.20。
  • 各版本PROOF均强预测总生存,每第10秩百分位HR为0.80至0.83,均p<0.001。

核心结论

  • 在大型患者队列中,患者报告的偏好可与ALSFRS-R可靠整合而不导致系统性偏倚。
  • 患者偏好可能提供常规测量之外的独特预后信息,有助于更全面理解医疗干预如何有效应对患者关切并改善对其最重要的事项。

研究设计与样本

  • 数据通过在线问卷在12个月期间获得,使用荷兰基于人群的登记库。
  • 患者对ALSFRS-R的功能域评分并排序各域重要性,初次邀请后2周重复问卷以评估重测信度。
  • 生存状态从市政人口登记处提取。
  • 共611例ALS患者随访生存,382例纳入重测信度研究。

主要发现

  • 使用不同偏好集的所有PROOF版本均显示优良信度,组内相关系数为0.89(95%CI 0.87-0.91)至0.97(95%CI 0.97-0.98),均p<0.001。
  • 基线至第2周无系统性差异,平均秩差范围为-1至-3(95%CI范围-8至2),均p>0.20。
  • 关于未来事件的偏好比关于当前症状的偏好变异更大。
  • 所有PROOF版本均强预测总生存,每第10秩百分位风险比为0.80至0.83(95%CI范围0.76-0.87),均p<0.001。
  • 与ALSFRS-R总分相比,PROOF在秩分层亚组间的生存曲线分离更均匀。

关键数值与推荐

  • PROOF各版本重测信度ICC为0.89(95%CI 0.87-0.91)至0.97(95%CI 0.97-0.98),均p<0.001。
  • 基线至第2周平均秩差为-1至-3(95%CI范围-8至2),均p>0.20。
  • PROOF各版本每第10秩百分位风险比为0.80至0.83(95%CI范围0.76-0.87),均p<0.001。

临床怎么用

  • 作者认为患者报告的偏好可与ALSFRS-R可靠整合,且可能提供常规测量之外的独特预后信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The Patient-Ranked Order of Function (PROOF) is a novel approach to account for patient-reported preferences in the evaluation of treatments of amyotrophic lateral sclerosis (ALS). In this study, we assess the reliability and prognostic value of different sets of patient-reported preferences that can be used for the PROOF end point. METHODS: Data were obtained through online surveys over the course of 12 months using the population-based registry of the Netherlands. Patients were asked to score functional domains of the ALS Functional Rating Scale (ALSFRS-R) and rank the order of importance of each domain. Two weeks after the initial invite, the questionnaire was repeated to evaluate test-retest reliability. Vital status was extracted from the municipal population register. RESULTS: In total, 611 patients with ALS were followed up for survival and 382 patients were included in the test-retest reliability study. All versions of PROOF, using different sets of preferences, resulted in excellent reliability (intraclass correlation coefficients ranged from 0.89 [95% CI 0.87-0.91] to 0.97 [95% CI 0.97-0.98], all p < 0.001), without systematic differences between baseline and week 2 (mean rank difference range -1 to -3 [95% CI range -8 to 2], all p > 0.20). Preferences about future events were more variable than preferences about current symptoms. All versions of PROOF strongly predicted overall survival (hazard ratios per 10th rank percentile ranged from 0.80 to 0.83 [95% CI range 0.76-0.87], all p < 0.001) and had a more even separation of survival curves between rank-stratified subgroups compared with the ALSFRS-R total score. DISCUSSION: In a large cohort of patients, we show how patient-reported preferences can be measured and integrated reliably with the ALSFRS-R without leading to systematic bias. Patient preferences may provide unique prognostic information in addition to what is already measured conventionally. This could provide a more comprehensive understanding of how medical interventions effectively address the patient's concerns and improve what matters most to them.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. van Eijk RPA, van den Berg LH, Lu Y, et al. Cultivating Patient Preferences in ALS Clinical Trials: Reliability and Prognostic Value of the Patient-Ranked Order of Function. Neurology. 2024. PMID: 38875513. doi:10.1212/WNL.0000000000209502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。